Wednesday, October 21, 2020

Pfizer COVID-19 vaccine rolls off production line amid hopes for emergency approval ; HHS Secretary says COVID-19 vaccine, treatment may be ‘weeks away’ , and other C-Virus Updates

Pfizer COVID-19 vaccine rolls off production line amid hopes for emergency approval:
Pfizer has already made “several hundred thousand doses” of a potential coronavirus vaccine as it prepares to seek emergency use in the US by November.
The drugmaker told the Mail on Sunday that scientists in its main British lab have also unearthed drugs that could provide a potential complete cure for COVID-19, as opposed to merely a preventative vaccine.
The firm’s UK boss, Ben Osborn, said the company is manufacturing the huge stockpile of its current vaccine candidate in Belgium “at risk and at scale,” calling it “tremendously exciting.” --->READ MORE HERE
HHS Secretary says COVID-19 vaccine, treatment may be ‘weeks away’:
Health and Human Services Secretary Alex Azar said Sunday that antibody treatments and vaccines for the coronavirus could be just “weeks away.”
“Hang in there with us. We are so close,” Azar told NBC’s “Meet the Press” as he warned of “mitigation fatigue” from “tired” Americans giving up on safety measures.
“We are weeks away from monoclonal antibodies for you, for safe and effective vaccines,” he said, urging viewers to help “bridge the gap” by maintaining mask-wearing and social distancing until then.
“The American people have given so much,” he told host Chuck Todd. “They’ve been locked down. They’ve been isolated and they’re tired. But the point is we’re so close.” --->READ MORE HERE
Follow links below to related stories and resources:

Eli Lilly and Johnson & Johnson have paused COVID-19 vaccine trials. Why experts say that's reassuring, not frightening

Is it the flu or COVID-19? How to tell the difference

USA TODAY: Coronavirus Updates

WSJ: Coronavirus Live Updates

YAHOO NEWS: Coronavirus Live Updates

NEW YORK POST: Coronavirus The Latest

If you like what you see, please "Like" us on Facebook either here or here. Please follow us on Twitter here.


No comments: